Copyright
©The Author(s) 2021.
World J Transplant. Mar 18, 2021; 11(3): 54-69
Published online Mar 18, 2021. doi: 10.5500/wjt.v11.i3.54
Published online Mar 18, 2021. doi: 10.5500/wjt.v11.i3.54
Table 7 Risk score without OKT3 and daclizumab for the 5-yr development of cutaneous squamous cell carcinoma after transplantation
| Covariates | Category | Score |
| Age | 18-40 | 0 |
| 40-60 | 1 | |
| > 60 | 2 | |
| Sex | Female | 0 |
| Male | 2 | |
| HLA mismatch level | > 5 | 0 |
| ≤ 5 | 1 | |
| Race | White | 2 |
| Other | 0 | |
| Diagnosis | Restrictive myopathy | 1 |
| Heart re-transplant | 1 | |
| Hypertrophic myopathy | 1 | |
| Other | 0 | |
| Malignancy at listing | No | 0 |
| Yes | 1 | |
| Unknown | 0 |
- Citation: Nair N, Hu Z, Du D, Gongora E. Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients. World J Transplant 2021; 11(3): 54-69
- URL: https://www.wjgnet.com/2220-3230/full/v11/i3/54.htm
- DOI: https://dx.doi.org/10.5500/wjt.v11.i3.54